Albendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials.

<h4>Background</h4>Neurocysticercosis, infection of the brain with larvae of Taenia solium (pork tapeworm), is one of several forms of human cysticercosis caused by this organism. We investigated the role of albendazole and praziquantel in the treatment of patients with parenchymal neuro...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dimitrios K Matthaiou, Georgios Panos, Eleni S Adamidi, Matthew E Falagas
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2008
Materias:	Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270
Acceso en línea:	https://doaj.org/article/1b326de659bb4ea1946d919a2b1b66ef
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1b326de659bb4ea1946d919a2b1b66ef
record_format	dspace
spelling	oai:doaj.org-article:1b326de659bb4ea1946d919a2b1b66ef2021-12-02T20:23:55ZAlbendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials.1935-27271935-273510.1371/journal.pntd.0000194https://doaj.org/article/1b326de659bb4ea1946d919a2b1b66ef2008-03-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/18335068/?tool=EBIhttps://doaj.org/toc/1935-2727https://doaj.org/toc/1935-2735<h4>Background</h4>Neurocysticercosis, infection of the brain with larvae of Taenia solium (pork tapeworm), is one of several forms of human cysticercosis caused by this organism. We investigated the role of albendazole and praziquantel in the treatment of patients with parenchymal neurocysticercosis by performing a meta-analysis of comparative trials of their effectiveness and safety.<h4>Methods and principal findings</h4>We performed a search in the PubMed database, Cochrane Database of Controlled Trials, and in references of relevant articles. Six studies were included in the meta-analysis. Albendazole was associated with better control of seizures than praziquantel in the pooled data analysis, when the generic inverse variance method was used to combine the incidence of seizure control in the included trials (patients without seizures/[patients x years at risk]) (156 patients in 4 studies, point effect estimate [incidence rate ratio] = 4.94, 95% confidence interval 2.45-9.98). In addition, albendazole was associated with better effectiveness than praziquantel in the total disappearance of cysts (335 patients in 6 studies, random effects model, OR = 2.30, 95% CI 1.06-5.00). There was no difference between albendazole and praziquantel in reduction of cysts, proportion of patients with adverse events, and development of intracranial hypertension due to the administered therapy.<h4>Conclusions</h4>A critical review of the available data from comparative trials suggests that albendazole is more effective than praziquantel regarding clinically important outcomes in patients with neurocysticercosis. Nevertheless, given the relative scarcity of trials, more comparative interventional studies--especially randomized controlled trials--are required to draw a safe conclusion about the best regimen for the treatment of patients with parenchymal neurocysticercosis.Dimitrios K MatthaiouGeorgios PanosEleni S AdamidiMatthew E FalagasPublic Library of Science (PLoS)articleArctic medicine. Tropical medicineRC955-962Public aspects of medicineRA1-1270ENPLoS Neglected Tropical Diseases, Vol 2, Iss 3, p e194 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270
spellingShingle	Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 Dimitrios K Matthaiou Georgios Panos Eleni S Adamidi Matthew E Falagas Albendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials.
description	<h4>Background</h4>Neurocysticercosis, infection of the brain with larvae of Taenia solium (pork tapeworm), is one of several forms of human cysticercosis caused by this organism. We investigated the role of albendazole and praziquantel in the treatment of patients with parenchymal neurocysticercosis by performing a meta-analysis of comparative trials of their effectiveness and safety.<h4>Methods and principal findings</h4>We performed a search in the PubMed database, Cochrane Database of Controlled Trials, and in references of relevant articles. Six studies were included in the meta-analysis. Albendazole was associated with better control of seizures than praziquantel in the pooled data analysis, when the generic inverse variance method was used to combine the incidence of seizure control in the included trials (patients without seizures/[patients x years at risk]) (156 patients in 4 studies, point effect estimate [incidence rate ratio] = 4.94, 95% confidence interval 2.45-9.98). In addition, albendazole was associated with better effectiveness than praziquantel in the total disappearance of cysts (335 patients in 6 studies, random effects model, OR = 2.30, 95% CI 1.06-5.00). There was no difference between albendazole and praziquantel in reduction of cysts, proportion of patients with adverse events, and development of intracranial hypertension due to the administered therapy.<h4>Conclusions</h4>A critical review of the available data from comparative trials suggests that albendazole is more effective than praziquantel regarding clinically important outcomes in patients with neurocysticercosis. Nevertheless, given the relative scarcity of trials, more comparative interventional studies--especially randomized controlled trials--are required to draw a safe conclusion about the best regimen for the treatment of patients with parenchymal neurocysticercosis.
format	article
author	Dimitrios K Matthaiou Georgios Panos Eleni S Adamidi Matthew E Falagas
author_facet	Dimitrios K Matthaiou Georgios Panos Eleni S Adamidi Matthew E Falagas
author_sort	Dimitrios K Matthaiou
title	Albendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials.
title_short	Albendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials.
title_full	Albendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials.
title_fullStr	Albendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials.
title_full_unstemmed	Albendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials.
title_sort	albendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials.
publisher	Public Library of Science (PLoS)
publishDate	2008
url	https://doaj.org/article/1b326de659bb4ea1946d919a2b1b66ef
work_keys_str_mv	AT dimitrioskmatthaiou albendazoleversuspraziquantelinthetreatmentofneurocysticercosisametaanalysisofcomparativetrials AT georgiospanos albendazoleversuspraziquantelinthetreatmentofneurocysticercosisametaanalysisofcomparativetrials AT elenisadamidi albendazoleversuspraziquantelinthetreatmentofneurocysticercosisametaanalysisofcomparativetrials AT matthewefalagas albendazoleversuspraziquantelinthetreatmentofneurocysticercosisametaanalysisofcomparativetrials
_version_	1718374093405814784

Albendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials.

Ejemplares similares